Theravance Biopharma Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
TBPH$17.030.0%Stored close · as of Sep 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| | |
|---|---|
| | Page No. |
| PART I. FINANCIAL INFORMATION | |
| Item 1. Financial Statements (unaudited) | 3 |
| Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 | 3 |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023 | 4 |
| Condensed Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2024 and 2023 | 5 |
| Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 | 6 |
| Notes to Condensed Consolidated Financial Statements | 7 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 16 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 24 |
| Item 4. Controls and Procedures | 25 |
| | |
| PART II. OTHER INFORMATION | |
| Item 1. Legal Proceedings | 25 |
| Item 1A. Risk Factors | 26 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 58 |
| Item 5. Other Information | 58 |
| Item 6. Exhibits | 59 |
| Signatures | 60 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.